Nancy Simonian, MD, CEO, Syros Pharmaceuticals explains that by modulating components of super-enhancers, important genes that drive disease states may be able to be turned down. She references a recent study published in Cell that indicated a chromatin regulator called BRD4 was shown to have selective disruptions of super-enhancers over normal enhancers.